Datameds Ai (MEDS) closed at $0.74 on November 13, 2026, down 14.5% from the previous close, on volume of 5,832,540 shares (30-day average 1,712,636).
Data as of November 13, 2026.
DataMEDS AI GAAP EPS of $2.72, revenue of $2.67M
Seeking Alpha News (Fri, 13-Nov 9:32 PM ET)
ACCESS Newswire (Fri, 13-Nov 10:20 AM ET)
ACCESS Newswire (Mon, 9-Nov 6:00 AM ET)
ACCESS Newswire (Thu, 5-Nov 6:00 AM ET)
DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
ACCESS Newswire (Tue, 3-Nov 6:18 PM ET)
ACCESS Newswire (Mon, 2-Nov 6:00 AM ET)
ACCESS Newswire (Fri, 23-Oct 6:45 AM ET)
Business Wire (Thu, 22-Oct 8:00 AM ET)
ACCESS Newswire (Thu, 22-Oct 7:40 AM ET)
DataMeds Regains Compliance With NASDAQ Listing Standards
ACCESS Newswire (Tue, 20-Oct 6:00 AM ET)
DataMEDS AI Inc is a healthcare technology and pharmaceutical logistics company. The group simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. Its solutions provide a single, integrated platform for pharmacies, wholesale distribution, and a fulfillment network focused on Independent Pharmacies and Specialty Lite medications.
Datameds Ai trades on the NASDAQ stock market under the symbol MEDS.
As of November 13, 2026, MEDS stock price declined to $0.74 with 5,832,540 million shares trading.
MEDS has a beta of -4.23, meaning it tends to be less sensitive to market movements. MEDS has a correlation of 0.02 to the broad based SPY ETF.
MEDS has a market cap of $2.38 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that MEDS belongs to (by Net Assets): VXF.
MEDS support price is $.77 and resistance is $.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEDS shares will trade within this expected range on the day.
